USFDA appeal for critical cancer drugs puts these Indian Pharma shares in focus

Shares of three pharmaceutical companies Cipla Ltd., Alkem Laboratories Ltd. and Zydus Lifesciences Ltd. are in focus on Tuesday, June 23, as the US drug regulator has likely approached Indian manufacturers for a cancer treatment drug due to its shortage, as per a Mint report, which cited sources.

The US Food and Drug Administration (USFDA) has approached Indian pharma manufacturers for ifofamide, a drug used in treating testicular, bladder and lung cancers, as per the Mint report.

The drug shortage is caused by a technical disruption at Baxter International’s contract manufacturing site and due to supply chain disruptions because of the West Asia war, the report stated. The supply is expected to remain limited through 2026.
The US drug regulator has reached out to Indian manufacturers via the Indian Drug Manufacturers’ Association (IDMA), the Mint report stated. It prefers FDA-registered facilities but is open to non-registered Indian plants with good compliance history.
While the report did not mention specific companies, shares of listed firms such as Cipla, Zydus Life, Alkem Labs will be in focus on Tuesday.

Shares of Cipla ended 5% higher on Monday at ₹1,417. The stock is still down 5.6% so far for the year.

Shares of Alkem Laboratories ended little changed on Monday at ₹5,370. The stock has remained little changed so far this year, declining 2%.

Shares of Zydus Lifesciences also ended 1.4% higher on Monday at ₹1,085.7. The stock has risen 20% so far in 2026.

Also Read: Asian Paints, HUL, five other stocks to trade ex-dividend from today; Details here